Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs

We present here an innovative modular and outsourced model of drug research and development for microRNA oligonucleotide therapeutics (miRNA ONTs). This model is being implemented by a biotechnology company, namely AptamiR Therapeutics, in collaboration with Centers of Excellence in Academic Institu...

Descripción completa

Detalles Bibliográficos
Autores principales: Thibonnier, Marc, Ghosh, Sujoy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138879/
https://www.ncbi.nlm.nih.gov/pubmed/37108289
http://dx.doi.org/10.3390/ijms24087126
_version_ 1785032811757961216
author Thibonnier, Marc
Ghosh, Sujoy
author_facet Thibonnier, Marc
Ghosh, Sujoy
author_sort Thibonnier, Marc
collection PubMed
description We present here an innovative modular and outsourced model of drug research and development for microRNA oligonucleotide therapeutics (miRNA ONTs). This model is being implemented by a biotechnology company, namely AptamiR Therapeutics, in collaboration with Centers of Excellence in Academic Institutions. Our aim is to develop safe, effective and convenient active targeting miRNA ONT agents for the metabolic pandemic of obesity and metabolic-associated fatty liver disease (MAFLD), as well as deadly ovarian cancer.
format Online
Article
Text
id pubmed-10138879
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101388792023-04-28 Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs Thibonnier, Marc Ghosh, Sujoy Int J Mol Sci Hypothesis We present here an innovative modular and outsourced model of drug research and development for microRNA oligonucleotide therapeutics (miRNA ONTs). This model is being implemented by a biotechnology company, namely AptamiR Therapeutics, in collaboration with Centers of Excellence in Academic Institutions. Our aim is to develop safe, effective and convenient active targeting miRNA ONT agents for the metabolic pandemic of obesity and metabolic-associated fatty liver disease (MAFLD), as well as deadly ovarian cancer. MDPI 2023-04-12 /pmc/articles/PMC10138879/ /pubmed/37108289 http://dx.doi.org/10.3390/ijms24087126 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Hypothesis
Thibonnier, Marc
Ghosh, Sujoy
Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs
title Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs
title_full Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs
title_fullStr Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs
title_full_unstemmed Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs
title_short Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs
title_sort strategy for pre-clinical development of active targeting microrna oligonucleotide therapeutics for unmet medical needs
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138879/
https://www.ncbi.nlm.nih.gov/pubmed/37108289
http://dx.doi.org/10.3390/ijms24087126
work_keys_str_mv AT thibonniermarc strategyforpreclinicaldevelopmentofactivetargetingmicrornaoligonucleotidetherapeuticsforunmetmedicalneeds
AT ghoshsujoy strategyforpreclinicaldevelopmentofactivetargetingmicrornaoligonucleotidetherapeuticsforunmetmedicalneeds

Ejemplares similares